Head-to-head evidence
orforglipron vs PB-119
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
orforglipron · Foundayo
Marketed by Eli Lilly
NCT05803421 · Phase 3 · completed
The study is randomized and active-controlled with a large sample of 2,749 participants, but it is open-label rather than blinded. Its primary endpoint is a hard clinical cardiovascular outcome; however, the comparison cannot be judged because no results are currently available.
Next expected readout: May 2027 · NCT07613307 (registry estimate)
PB-119
Developed by PegBio
NCT04504396 · Phase 3 · completed
This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint, change in HbA1c, was clearly met, with PB-119 producing a significantly larger reduction than placebo (P<0.001).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · PB-119's landscape